Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an update.
On July 17, 2025, OKYO Pharma Limited announced it received $1.9 million in non-dilutive funding to accelerate the clinical development of urcosimod, its lead drug candidate for treating Neuropathic Corneal Pain (NCP). This funding will enable the company to advance key clinical milestones and expand research and development efforts without affecting shareholder equity, marking a significant step forward in addressing a critical unmet medical need in ocular pain treatment.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is listed on the NASDAQ Capital Market and is dedicated to discovering and developing novel molecules to address these ocular conditions.
Average Trading Volume: 182,641
Technical Sentiment Signal: Buy
Current Market Cap: $102.9M
See more data about OKYO stock on TipRanks’ Stock Analysis page.